Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Larry Zhou

Interventional Pain Medicine Louisville, KY Medical Doctor

NPI 1467441915 CMS profile 247617

1230 S Hurstbourne Pkwy, Unit 120, Louisville, KY 40222

Open in the dashboard

General payments

$2,176

81 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Larry Zhou of Louisville, KY is reported in the CMS Open Payments database as having received $2,176 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 36th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26 1
2023 General $337 5
2022 General $582 19
2021 General $370 15
2020 General $268 10
2019 General $593 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Larry Zhou
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Larry Zhou were reported at $26. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Larry Zhou Interventional Pain Medicine median Middle half National median
2019 $593 $684 $216–$2,079 $163
2020 $268 $382 $122–$1,109 $114
2021 $370 $552 $167–$1,554 $132
2022 $582 $605 $187–$1,924 $149
2023 $337 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $26 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $425 17 payments
  2. Medtronic, Inc. $341 7 payments
  3. AbbVie, Inc. $267 14 payments
  4. SPR Therapeutics, Inc $261 1 payment
  5. SI-BONE, Inc. $116 1 payment
  6. Allergan Inc. $108 7 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $102 4 payments
  8. Flowonix Medical Incorporated $94 2 payments
  9. Collegium Pharmaceutical, Inc. $91 7 payments
  10. Lilly USA, LLC $83 5 payments
  11. Other $287 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,915 80 payments
  2. Travel and Lodging $261 1 payment
Products named General payments · program years 2019–2025
  1. SPRINT PNS System $261 1 payment
  2. UBRELVY $249 13 payments
  3. VECTRIS $180 2 payments
  4. SYNCHROMEDII $166 4 payments
  5. SYNCHROMED Drug Infusion Systems $160 2 payments
  6. SYNCHROMED Drug Infusion Systems $143 2 payments
  7. NURTEC ODT $102 4 payments
  8. ASCENDA $97 12 payments
  9. Prometra II $94 2 payments
  10. XTAMPZA $91 7 payments
  11. Other $630 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

6,515

Median for Anesthesiology: 322

Drug cost

$131,038

Median for Anesthesiology: $8,738

Branded share of claims

49.3%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,479 $40,696
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,662 $31,925
Gabapentin Generic 944 $10,102
Oxycodone Hcl Generic 292 $9,596
Movantik Naloxegol Oxalate Brand 15 $9,235
Pregabalin Generic 227 $6,124
Naloxone Hcl Generic 103 $5,355
Fentanyl Generic 18 $3,150
Lidocaine Generic 21 $2,521
Tramadol Hcl Generic 265 $2,037

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$375,330

Medicare's payments for the services billed

Medicare patients

296

Average age 71

Services billed

3,904

186 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Depression 31%
Ischemic heart disease 30%
COPD 25%
Chronic kidney disease 22%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record